U.S. Markets close in 6 hrs 7 mins
  • S&P 500

    3,916.94
    -8.49 (-0.22%)
     
  • Dow 30

    31,918.74
    -43.12 (-0.13%)
     
  • Nasdaq

    13,568.16
    -29.81 (-0.22%)
     
  • Russell 2000

    2,285.79
    +1.41 (+0.06%)
     
  • Crude Oil

    63.05
    -0.17 (-0.27%)
     
  • Gold

    1,786.10
    -11.80 (-0.66%)
     
  • Silver

    28.08
    +0.15 (+0.53%)
     
  • EUR/USD

    1.2240
    +0.0071 (+0.5875%)
     
  • 10-Yr Bond

    1.4420
    +0.0530 (+3.82%)
     
  • Vix

    22.02
    +0.68 (+3.19%)
     
  • GBP/USD

    1.4174
    +0.0032 (+0.2296%)
     
  • USD/JPY

    106.0760
    +0.1940 (+0.1832%)
     
  • BTC-USD

    50,855.11
    +1,161.00 (+2.34%)
     
  • CMC Crypto 200

    1,018.39
    +23.73 (+2.39%)
     
  • FTSE 100

    6,679.81
    +20.84 (+0.31%)
     
  • Nikkei 225

    30,168.27
    +496.57 (+1.67%)
     

Recap: Synlogic Q3 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Synlogic (NASDAQ:SYBX) moved higher by 10.11% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 7.69% year over year to ($0.36), which beat the estimate of ($0.47).

Revenue of $0 decreased by 100.00% year over year, which missed the estimate of $280,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Nov 05, 2020

View more earnings on SYBX

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/5yiybtxn

Recent Stock Performance

Company's 52-week high was at $3.46

52-week low: $1.35

Price action over last quarter: down 2.79%

Company Profile

Synlogic Inc is a biopharmaceutical company focused on advancing the drug discovery and development platform for Synthetic Biotic medicines, which are designed using synthetic biology to genetically reprogram beneficial microbes to treat metabolic and inflammatory diseases and cancer.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.